1 One Year Post Exclusivity Adverse Event Review: Ofloxacin Ophthalmic Pediatric Advisory Committee Meeting September 15, 2004 Hari Cheryl Sachs, MD, FAAP.

Slides:

Advertisements

Similar presentations

Analysis of the ADVANCE Trial Sapna N. Patel UCSF Pharm. D. Candidate 2008 Preceptor Dr. Craig S. Stern March 28, 2008.

Advertisements

Dermatologic and Ophthalmic Drugs Advisory Committee July 12, Clinical Wrap-Up Denise Cook, M.D. Medical Officer Division of Dermatology and Dental.

Clinical Trials Medical Interventions

Safety Review for Plan B Daniel Davis, MD, MPH Division of Reproductive/Urologic Drugs.

1 One Year Post Exclusivity Adverse Event Review: Fentanyl Transdermal System Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting.

1 Drug Utilization for Immediate- and Modified Release Opioids in the U.S. Gianna C. Rigoni, Pharm.D., M.S. Epidemiologist Division of Surveillance, Research.

Postmarketing Risk Assessment of Drug Products Division of Drug Risk Evaluation Office of Drug Safety Center for Drug Evaluation and Research.

1 One Year Post Exclusivity Adverse Event Review: Atovaquone-Proguanil Pediatric Advisory Committee Meeting February 14, 2005 Alan M. Shapiro, MD, PhD,

1 One Year Post-Exclusivity Adverse Event Review: Ertapenem Pediatric Advisory Committee Meeting November 16, 2006 Alan M. Shapiro, MD, PhD, FAAP Medical.

Prescription Drug Abuse Sharon Hertz, M.D. Medical Officer Division of Anesthetic, Critical Care and Addiction Drug Products Food and Drug Administration.

1 The Chemoprevention of Sporadic Colorectal Cancer Issues Surrounding a Benefit/Risk Analysis in Clinical Trials Mark Avigan MD CM Medical Officer Division.

Abuse Liability of Hydromorphone Extended Release Capsules Silvia N. Calderon, Ph.D. Controlled Substance Staff Center for Drug Evaluation and Research.

1 Lotronex ® (alosetron HCl) Tablets Risk-Benefit Issues Victor F. C. Raczkowski, M.D. Director, Division of Gastrointestinal and Coagulation Drug Products.

1 One Year Post Exclusivity Adverse Event Review as Mandated by the Best Pharmaceuticals for Children Act Presented at the Psychopharmacologic Drugs Advisory.

DSaRM Advisory Committee May 18, 2005 Active Surveillance for Drug Safety Signals: Past, Present, and Future Mary Willy, Ph.D. Division of Drug Risk Evaluation.

An Update on NSAID Labeling and Data Review DSaRM Advisory Committee February 10, 2006 Sharon Hertz, M.D. Deputy Director Division of Anesthesia, Analgesia,

Center for Drug Evaluation and Research Patterns of Prescription Weight-Loss Drug Use Endocrinologic and Metabolic Drugs Advisory Committee Meeting Rockville,

Adverse Event Tracking as mandated by the Best Pharmaceuticals for Children Act Dr. Solomon Iyasu Medical Team Leader Division of Pediatric Drug Development.

1 One Year Post Exclusivity Adverse Event Review: Orlistat Pediatric Advisory Committee Meeting February 14, 2005 Hari Cheryl Sachs, MD, FAAP Medical Officer.

1 One Year Post Exclusivity Adverse Event Review: Alendronate Pediatric Advisory Committee Meeting September 15, 2004 Hari Cheryl Sachs, MD, FAAP Medical.

Overview of Issues for Psychopharmacological Drugs Advisory Committee June 16, 2003 WBC Monitoring for Clozapine Judith A. Racoosin, MD, MPH Safety Team.

Postmarketing Safety Assessment of Osteonecrosis of the Jaw Pamidronate & Zoledronic Acid Division of Drug Risk Evaluation Office of Drug Safety FDA Carol.

Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.

Pediatric Advisory Committee April 11, Update to the Committee: Oxybutynin Central Anticholinergic Effects Pediatric Advisory Committee Meeting.

Food and Drug Administration Division of Pulmonary and Allergy Drug Products Pulmonary-Allergy Drugs Advisory Committee Meeting July 13, 2005 Safety of.

1 One Year Post-Exclusivity Adverse Event Review: Tolterodine Pediatric Advisory Committee Meeting June 29, 2005 Lawrence Grylack, MD Medical Officer Division.

Joint Dermatologic and Ophthalmic Drugs & Drug Safety and Risk Management Advisory Committee February 26 & 27, Overview Isotretinoin Pregnancy Exposures:

1 Update to Post Exclusivity Pediatric Adverse Event Review: Simvastatin Pediatric Advisory Committee Meeting November 16, 2006 Jean Temeck, MD, Acting.

Food and Drug Administration Division of Pulmonary and Allergy Drug Products Pediatric Exclusivity 1-Year Adverse Event Reporting for Drug Products Containing.

Pediatric Advisory Committee Meeting September 15, 2004

1 One Year Post Exclusivity Adverse Event Review: Fexofenadine Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004.

1 One Year Post Exclusivity Adverse Event Review: Topotecan Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004.

1 One Year Post-Exclusivity Adverse Event Review: Paricalcitol, Zolmitriptan, Dorzolamide, and Leflunomide Pediatric Advisory Committee Meeting June 29,

1 One Year Post Exclusivity Adverse Event Review Update: Orlistat Pediatric Advisory Committee Meeting April 11, 2007 Hari Cheryl Sachs, MD, FAAP Medical.

Post-Marketing AE Reports of Topical Calcineurin Inhibitors Pediatric Advisory Subcommittee of the Anti-Infective Drugs Advisory Committee Marilyn R. Pitts,

1 One Year Post Exclusivity Adverse Event Review: Esmolol Pediatric Advisory Committee Meeting February 14, 2005 Lawrence Grylack, MD Medical Officer Division.

1 One Year Post Exclusivity Adverse Event Review: Budesonide & Fluticasone Pediatric Advisory Committee Meeting September 15, 2004 Joyce Weaver, PharmD,

Cardiovascular Risk and NSAIDs Arthritis Advisory Committee Meeting November 29, 2006 Sharon Hertz, M.D. Deputy Director Division of Analgesia, Anesthesia,

1 One Year Post-Exclusivity Adverse Event Review: Norgestimate/ethinyl estradiol Pediatric Advisory Committee Meeting June 29, 2005 Hari Cheryl Sachs,

1 One Year Post Exclusivity Adverse Event Review: Carboplatin Pediatric Advisory Committee Meeting November 18, 2005 Susan McCune, M.D. Medical Officer.

Food and Drug Administration Center for Drug Evaluation and Research Lessons Learned from Growth Studies with Orally Inhaled and Intranasal Corticosteroids.

1 One Year Post-Exclusivity Adverse Event Review: Meloxicam Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.

History of Pediatric Labeling

1 One Year Post-Exclusivity Adverse Event Review: Rosiglitazone Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.

1 One Year Post-Exclusivity Adverse Event Review: Insulin Aspart Recombinant Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs,

Focus Area 17: Medical Product Safety Progress Review November 5, 2003.

1 One Year Post Exclusivity Adverse Event Monitoring as mandated by the Best Pharmaceuticals for Children Act Dr. Solomon Iyasu Medical Team Leader Dr.

Food and Drug Administration Amendments Act of 2007 Reauthorization of Pediatric Initiatives Lisa L. Mathis, M.D. Pediatric and Maternal Health Staff Office.

1 One Year Post Exclusivity Adverse Event Review: Sumatriptan Pediatric Advisory Committee Meeting November 18, 2005 Susan McCune, M.D. Medical Officer.

1 One Year Post Exclusivity Adverse Event Review: Ciprofloxacin Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004.

Initiatives Drive Pediatric Drug Development January 30, 2002.

1 Robert J. Spiegel, M.D. Sr. V. P. Medical Affairs Chief Medical Officer Schering Plough FDA ADVISORY COMMITTEE 5/11/01.

1 One Year Post Exclusivity Adverse Event Review: Venlafaxine Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004.

Efficacy of Topical Azithromycin & Cyclosporine A(CsA) vs CsA Alone in the Treatment of Dry Eyes Associated with Blepharitis Kenneth A. Beckman, M.D.,

Zelnorm ® (tegaserod) Division of Gastrointestinal and Coagulation Drug Products Division of Drug Risk Evaluation Gary Della’Zanna, D.O., M.Sc., F.A.C.O.S.

1 Overview of Pediatric Safety Reporting and Role of the Committee Pediatric Advisory Committee Meeting November 18, 2005 Solomon Iyasu, M.D., M.P.H. Acting.

1 One Year Post Exclusivity Adverse Event Review: Benazepril Pediatric Advisory Committee Meeting February 14, 2005 Lawrence Grylack, MD Medical Officer.

1 Update to Post-Exclusivity Pediatric Adverse Event Review: Oxybutynin Pediatric Advisory Committee Meeting November 16, 2006 Lisa Mathis, MD, Associate.

Overview of Pediatric Drug Development Dianne Murphy, MD Director Office of Counterterrorism and Pediatric Drug Development Center for Drug Evaluation.

1 One Year Post Exclusivity Adverse Event Review: Glimepiride Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.

1 Update to Post Exclusivity Pediatric Adverse Event Review: Atorvastatin Pediatric Advisory Committee Meeting November 16, 2006 Jean Temeck, MD, Acting.

Pediatric Advisory Committee: Overview of Role and Evolution of Process Dr. Dianne Murphy Director, Office of Pediatric Therapeutics, OC, FDA November.

Dorzolamide A topical Carbonic anhydrase inhibitor. Ampholytic characteristics, hence good corneal penetration (depot effect achieved in cornea). Achieves.

1 One Year Post Exclusivity Adverse Event Review: Glyburide-Metformin Pediatric Advisory Committee Meeting February 14, 2005 Hari Cheryl Sachs, MD, FAAP.

Accutane ® Use and Epidemiology John E. La Flore, MD, MSPH Vice President, Drug Safety & Risk Management Hoffmann-La Roche Inc.

27 June 2000Victor F. C. Raczkowski, M.D.1 Risk-Management Options Victor F. C. Raczkowski, M.D., M.S. Gastrointestinal Drugs Advisory Committee 27 June.

Clinical Trials Medical Interventions

Clinical Trials.

Endari (L-Glutamine)for sickle Cell Disease

Pediatric Therapeutics Still working to get it right for kids

Presentation transcript:

1 One Year Post Exclusivity Adverse Event Review: Ofloxacin Ophthalmic Pediatric Advisory Committee Meeting September 15, 2004 Hari Cheryl Sachs, MD, FAAP Medical Officer Division of Pediatric Drug Development Center for Drug Evaluation and Research Food and Drug Administration

2 Background Drug Information Moiety: Ocuflox ® (ofloxacin) Therapeutic Category: ophthalmic anti-infective Sponsor: Allergan Adult and Pediatric Indications: treatment of conjunctivitis and corneal ulcers for susceptible bacteria in patients > 1 year Dosage: 1-2 drops at frequent intervals depending on condition Original Market Approval: July 30, 1993 Pediatric Exclusivity Granted: March 12, 2003

3 Drug Use Trends in Outpatient Settings: Ofloxacin Comprises 12 % of total 11.6 million prescriptions for medium and broad spectrum ophthalmics during exclusivity period (decreased from 20 % prior two years) 1 While total dispensed prescriptions have decreased from 2.2 million to 1.4 million during April March , pediatric usage has remained steady. 2 Pediatric patients (ages 1-16) accounted for approximately one third of total U.S. prescriptions of Ocuflox® between April 2003 – March 2004 (460,752). 1,2* 1 IMS Health, National Prescription Audit Plus , On-Line, Apr 2001 – Mar 2004, Data Extracted May AdvancePCS  Dimension Rx, On-Line, Apr 2002 – Mar 2004, Data Extracted May 2004 *Calculation based on application of proportions of pediatric ofloxacin prescriptions in AdvancePCS  to IMS Health, National Prescription Audit Plus  to estimate number of ofloxacin prescriptions dispensed nationwide to pediatric population

4 Drug Use Trends in Outpatient Settings: Ofloxacin Prescribers: Ophthalmologists (39 %) and Pediatricians (26 %) 1 Pediatric Diagnosis: Conjunctivitis (77 % drug mentions) 2 1 IMS Health, National Prescription Audit Plus , On-Line, Apr Mar 2004, Data Extracted May IMS Health, National Disease and Therapeutic Index , CD-Rom, Apr Mar 2004, Data Extracted May 2004

5

6 Pediatric Exclusivity Studies: Ofloxacin One week, multicenter, randomized, double blind, parallel group trial comparing ofloxacin 0.3 % to trimethoprim sulfate/polymyxin b in neonates. –Cure rate= 60 % (vehicle 70 %) –Safety comparable to prior studies –Unable to determine from data submitted why clinical cure rate was low No label change resulted

7 Pregnancy Category C Pediatric Use: Arthropathy in immature animals from oral (not topical) quinolones Warning: Hypersensitivity/anaphylaxis Adverse Reactions: –Transient ocular burning or discomfort –Other local symptoms (stinging, redness itching, chemical conjunctivitis/keratitis, edema, tearing, dryness and eye pain) –Visual changes- photophobia, blurred vision –Rare dizziness and nausea Relevant Safety Labeling

8 Adverse Event Reports Since Market Approval: Ofloxacin July 1993 – April 2004 Total number of reports, all ages: –66 reports (50 US) 18 serious (7 US) 4 deaths (0 US) Pediatric reports: –3 reports (2 US) 1 serious (0 US) 0 deaths Raw counts (US reports are in parenthesis)- includes duplicates

9 Adverse Events during the One-Year Post-Exclusivity Period: Ofloxacin March 2003 – April 2004 Adult (2) –Deafness neurosensory (1) –Hearing loss (1) Pediatric (1) –Corneal deposits (1) All events are unlabeled

10 Pediatric Adverse Event (n=1) 6 year old male Treatment for vernal conjunctivitis with topical ofloxacin ointment and drops TID for 3 weeks, along with prednisolone Developed dense, white, sharply demarcated corneal deposits treated with corneal scraping

11 Summary With one event, no meaningful conclusion can be drawn. This completes the one-year post- exclusivity adverse event monitoring as mandated by BPCA. FDA will continue its routine monitoring of adverse events for this drug.